Back

Silicon-rhodamine functionalized evocalcet probes (EvoSiR) potently and selectively label calcium sensing receptors (CaSR) in vitro, in vivo and ex vivo

Batora, D.; Fischer, J. P.; Kaderli, R. M.; Varga, M.; Lochner, M.; Gertsch, J.

2024-02-25 pharmacology and toxicology
10.1101/2024.02.22.581561 bioRxiv
Show abstract

The calcium sensing receptor (CaSR) is a ubiquitously expressed G-protein coupled receptor (GPCR) that regulates extracellular calcium signals via the parathyroid glands. CaSR has recently also been implicated in non-calcitropic pathophysiologies like asthma, gut inflammation and cancer. To date, molecular tools that enable the bioimaging of CaSR in tissues are lacking. Based on in silico analyses of available structure-activity relationship data on CaSR ligands, we designed and prepared silicon-rhodamine (SiR) conjugates of the clinically approved drug evocalcet. The new probes EvoSiR4 and EvoSiR6, with differing linker lengths at the evocalcet carboxyl end, both showed a 6-fold and 3-fold increase in potency towards CaSR (EC50<45 nM) compared to evocalcet and the evocalcet-linker conjugate, respectively, in a FLIPR(R)-based cellular functional assay. The specificity of the EvoSiR probes towards CaSR binding and the impact of albumin was evaluated in live cell experiments. Both probes showed strong albumin binding, which facilitated the clearance of nonspecific binding interactions. Accordingly, in zebrafish embryos, EvoSiR4 specifically labelled the high CaSR expressing neuromasts of the lateral line in vivo. EvoSiR4 was also assessed in human parathyroid tissues ex vivo, showing a specific absolute CaSR associated fluorescence compared to parathyroid autofluorescence. In summary, functionalization of evocalcet by SiR led to the preparation of potent and specific fluorescent CaSR probes. EvoSiR4 is a versatile small molecular probe that can be employed in CaSR-related biomedical analyses where antibodies are not applicable.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
ACS Central Science
66 papers in training set
Top 0.1%
18.1%
2
Angewandte Chemie International Edition
81 papers in training set
Top 0.1%
12.0%
3
Journal of the American Chemical Society
199 papers in training set
Top 0.6%
10.2%
4
Nature Communications
4913 papers in training set
Top 23%
8.2%
5
ACS Nano
99 papers in training set
Top 1%
3.5%
50% of probability mass above
6
Advanced Science
249 papers in training set
Top 7%
3.0%
7
Light: Science & Applications
16 papers in training set
Top 0.2%
3.0%
8
Chemical Science
71 papers in training set
Top 0.6%
2.5%
9
ChemMedChem
15 papers in training set
Top 0.2%
2.4%
10
Nature Chemical Biology
104 papers in training set
Top 1%
2.0%
11
Journal of Medicinal Chemistry
68 papers in training set
Top 0.5%
2.0%
12
Nature Chemistry
34 papers in training set
Top 0.4%
1.7%
13
Small
70 papers in training set
Top 0.5%
1.6%
14
Communications Chemistry
39 papers in training set
Top 0.4%
1.4%
15
Scientific Reports
3102 papers in training set
Top 63%
1.4%
16
ACS Sensors
45 papers in training set
Top 0.9%
1.3%
17
ACS Medicinal Chemistry Letters
16 papers in training set
Top 0.4%
1.3%
18
ACS Chemical Biology
150 papers in training set
Top 1%
1.3%
19
Advanced Healthcare Materials
71 papers in training set
Top 1%
1.2%
20
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.7%
0.9%
21
Analytical Chemistry
205 papers in training set
Top 2%
0.9%
22
ACS Chemical Neuroscience
60 papers in training set
Top 2%
0.9%
23
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 43%
0.8%
24
eLife
5422 papers in training set
Top 59%
0.7%
25
Nucleic Acids Research
1128 papers in training set
Top 18%
0.7%
26
Science Advances
1098 papers in training set
Top 31%
0.7%
27
Bioorganic & Medicinal Chemistry Letters
10 papers in training set
Top 0.4%
0.7%
28
Journal of Controlled Release
39 papers in training set
Top 1%
0.7%
29
Communications Biology
886 papers in training set
Top 30%
0.6%
30
Advanced Materials
53 papers in training set
Top 2%
0.6%